HBV Antiviral Composition Blocking miR-4453 at the 5′ Epsilon Signal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus (HBV) infection do not effectively inhibit the replication of the virus, as there is a lack of knowledge on microRNAs that directly promote HBV replication, and existing therapies do not target the specific mechanisms involved in HBV RNA processing and stability.
Innovation Solution
A composition comprising an inhibitory substance, such as an antisense oligonucleotide, siRNA, or locked nucleic acid, targeting the 5′ epsilon signal sequence in the pregenomic RNA of HBV to inhibit the function of microRNA miR-4453, which is essential for HBV replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for hepatitis B virus infection are used, then the virus replication is not effectively inhibited, but the lack of knowledge on microRNAs that directly promote HBV replication limits treatment effectiveness
Solution Approach 1:
The patent identifies and targets miR-4453, a specific microRNA that promotes HBV replication, before it can effectively drive viral replication. By preparing and administering an inhibitory substance against this specific miRNA, the treatment proactively prevents rather than reacts to viral replication, resolving the contradiction between current treatment effectiveness and the lack of mechanistic knowledge.
Solution Approach 2:
The patent changes the target parameter from general HBV replication inhibition to specific inhibition of miR-4453 function. This parameter change allows the treatment to address the root cause identified through research, transforming the approach from empirical treatment to mechanism-based therapy, thereby improving reliability while filling the knowledge gap.
2Ease of manufacture
If existing therapies are used, then treatment is provided, but they do not target the specific mechanisms involved in HBV RNA processing and stability
Solution Approach 1:
The patent applies local quality by targeting a specific local element (miR-4453) within the HBV replication mechanism rather than treating the entire viral system generally. The inhibitory substance is designed to specifically interfere with miR-4453 binding to the 5' epsilon signal sequence, providing precise mechanism targeting while maintaining treatment availability through established nucleic acid therapy platforms.
Solution Approach 2:
The patent segments the HBV replication mechanism into specific functional components, identifying miR-4453 as a critical segment that promotes viral RNA processing and stability. By isolating and targeting this specific segment, the therapy achieves high precision in mechanism targeting while remaining manufacturable using standard nucleic acid-based approaches.
3Productivity
If miR-4453 is inhibited, then HBV replication is suppressed, but the complexity of developing and administering the inhibitory substance increases
Solution Approach 1:
The patent uses an inhibitory substance (such as an antisense oligonucleotide or miRNA inhibitor) as an intermediary to block miR-4453 function. This intermediary approach simplifies the overall strategy by using well-established nucleic acid-based tools that can be readily administered, avoiding the need for complex viral vectors or protein-based therapies while achieving effective HBV replication suppression.
Data Source
AI summary
The present invention provides a pharmaceutical composition for treating hepatitis B. The present invention provides a composition for inhibiting the replication of hepatitis B virus and a pharmaceutical composition for treating hepatitis B virus infection, each comprising an inhibitory substance against microRNA binding to the 5′ epsilon signal sequence in the pregenomic RNA of hepatitis B virus.